Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 188

1.

Deuterium-reinforced linoleic acid lowers lipid peroxidation and mitigates cognitive impairment in the Q140 knock in mouse model of Huntington's disease.

Hatami A, Zhu C, Relaño-Gines A, Elias C, Galstyan A, Jun M, Milne G, Cantor CR, Chesselet MF, Shchepinov MS.

FEBS J. 2018 Jun 22. doi: 10.1111/febs.14590. [Epub ahead of print]

PMID:
29933522
2.

Chronic nicotine improves cognitive and social impairment in mice overexpressing wild type α-synuclein.

Subramaniam SR, Magen I, Bove N, Zhu C, Lemesre V, Dutta G, Elias CJ, Lester HA, Chesselet MF.

Neurobiol Dis. 2018 Sep;117:170-180. doi: 10.1016/j.nbd.2018.05.018. Epub 2018 Jun 1.

PMID:
29859873
3.

Human Neural Stem Cell Transplantation Rescues Functional Deficits in R6/2 and Q140 Huntington's Disease Mice.

Reidling JC, Relaño-Ginés A, Holley SM, Ochaba J, Moore C, Fury B, Lau A, Tran AH, Yeung S, Salamati D, Zhu C, Hatami A, Cepeda C, Barry JA, Kamdjou T, King A, Coleal-Bergum D, Franich NR, LaFerla FM, Steffan JS, Blurton-Jones M, Meshul CK, Bauer G, Levine MS, Chesselet MF, Thompson LM.

Stem Cell Reports. 2018 Jan 9;10(1):58-72. doi: 10.1016/j.stemcr.2017.11.005. Epub 2017 Dec 7.

4.

A Molecular Tweezer Ameliorates Motor Deficits in Mice Overexpressing α-Synuclein.

Richter F, Subramaniam SR, Magen I, Lee P, Hayes J, Attar A, Zhu C, Franich NR, Bove N, De La Rosa K, Kwong J, Klärner FG, Schrader T, Chesselet MF, Bitan G.

Neurotherapeutics. 2017 Oct;14(4):1107-1119. doi: 10.1007/s13311-017-0544-9.

5.

Effects of decreased dopamine transporter levels on nigrostriatal neurons and paraquat/maneb toxicity in mice.

Richter F, Gabby L, McDowell KA, Mulligan CK, De La Rosa K, Sioshansi PC, Mortazavi F, Cely I, Ackerson LC, Tsan L, Murphy NP, Maidment NT, Chesselet MF.

Neurobiol Aging. 2017 Mar;51:54-66. doi: 10.1016/j.neurobiolaging.2016.11.015. Epub 2016 Dec 1.

6.

Gut Microbiota Regulate Motor Deficits and Neuroinflammation in a Model of Parkinson's Disease.

Sampson TR, Debelius JW, Thron T, Janssen S, Shastri GG, Ilhan ZE, Challis C, Schretter CE, Rocha S, Gradinaru V, Chesselet MF, Keshavarzian A, Shannon KM, Krajmalnik-Brown R, Wittung-Stafshede P, Knight R, Mazmanian SK.

Cell. 2016 Dec 1;167(6):1469-1480.e12. doi: 10.1016/j.cell.2016.11.018.

7.

A de novo compound targeting α-synuclein improves deficits in models of Parkinson's disease.

Wrasidlo W, Tsigelny IF, Price DL, Dutta G, Rockenstein E, Schwarz TC, Ledolter K, Bonhaus D, Paulino A, Eleuteri S, Skjevik ÅA, Kouznetsova VL, Spencer B, Desplats P, Gonzalez-Ruelas T, Trejo-Morales M, Overk CR, Winter S, Zhu C, Chesselet MF, Meier D, Moessler H, Konrat R, Masliah E.

Brain. 2016 Dec;139(Pt 12):3217-3236. Epub 2016 Sep 27.

8.

Striatal cholinergic dysfunction as a unifying theme in the pathophysiology of dystonia.

Eskow Jaunarajs KL, Bonsi P, Chesselet MF, Standaert DG, Pisani A.

Prog Neurobiol. 2015 Apr;127-128:91-107. doi: 10.1016/j.pneurobio.2015.02.002. Epub 2015 Feb 17. Review.

9.

Social Cognition Impairments in Mice Overexpressing Alpha-Synuclein Under the Thy1 Promoter, a Model of Pre-manifest Parkinson's Disease.

Magen I, Torres ER, Dinh D, Chung A, Masliah E, Chesselet MF.

J Parkinsons Dis. 2015;5(3):669-680. doi: 10.3233/JPD-140503.

10.

Intranasal NAP (davunetide) decreases tau hyperphosphorylation and moderately improves behavioral deficits in mice overexpressing α-synuclein.

Magen I, Ostritsky R, Richter F, Zhu C, Fleming SM, Lemesre V, Stewart AJ, Morimoto BH, Gozes I, Chesselet MF.

Pharmacol Res Perspect. 2014 Oct;2(5):e00065. doi: 10.1002/prp2.65. Epub 2014 Aug 6.

11.

Transgenic rodent models to study alpha-synuclein pathogenesis, with a focus on cognitive deficits.

Hatami A, Chesselet MF.

Curr Top Behav Neurosci. 2015;22:303-30. doi: 10.1007/7854_2014_355. Review.

PMID:
25218491
12.

A GCase chaperone improves motor function in a mouse model of synucleinopathy.

Richter F, Fleming SM, Watson M, Lemesre V, Pellegrino L, Ranes B, Zhu C, Mortazavi F, Mulligan CK, Sioshansi PC, Hean S, De La Rosa K, Khanna R, Flanagan J, Lockhart DJ, Wustman BA, Clark SW, Chesselet MF.

Neurotherapeutics. 2014 Oct;11(4):840-56. doi: 10.1007/s13311-014-0294-x.

13.

Region specific mitochondrial impairment in mice with widespread overexpression of alpha-synuclein.

Subramaniam SR, Vergnes L, Franich NR, Reue K, Chesselet MF.

Neurobiol Dis. 2014 Oct;70:204-13. doi: 10.1016/j.nbd.2014.06.017. Epub 2014 Jul 10.

14.

Sleep dysfunction and EEG alterations in mice overexpressing alpha-synuclein.

McDowell KA, Shin D, Roos KP, Chesselet MF.

J Parkinsons Dis. 2014;4(3):531-539. doi: 10.3233/JPD-140374.

15.

Chronic administration of cholesterol oximes in mice increases transcription of cytoprotective genes and improves transcriptome alterations induced by alpha-synuclein overexpression in nigrostriatal dopaminergic neurons.

Richter F, Gao F, Medvedeva V, Lee P, Bove N, Fleming SM, Michaud M, Lemesre V, Patassini S, De La Rosa K, Mulligan CK, Sioshansi PC, Zhu C, Coppola G, Bordet T, Pruss RM, Chesselet MF.

Neurobiol Dis. 2014 Sep;69:263-75. doi: 10.1016/j.nbd.2014.05.012. Epub 2014 May 18.

16.

Vocalization deficits in mice over-expressing alpha-synuclein, a model of pre-manifest Parkinson's disease.

Grant LM, Richter F, Miller JE, White SA, Fox CM, Zhu C, Chesselet MF, Ciucci MR.

Behav Neurosci. 2014 Apr;128(2):110-21. doi: 10.1037/a0035965.

17.

Impaired baroreflex function in mice overexpressing alpha-synuclein.

Fleming SM, Jordan MC, Mulligan CK, Masliah E, Holden JG, Millard RW, Chesselet MF, Roos KP.

Front Neurol. 2013 Jul 23;4:103. doi: 10.3389/fneur.2013.00103. eCollection 2013.

18.

Mitochondrial dysfunction and oxidative stress in Parkinson's disease.

Subramaniam SR, Chesselet MF.

Prog Neurobiol. 2013 Jul-Aug;106-107:17-32. doi: 10.1016/j.pneurobio.2013.04.004. Epub 2013 Apr 30. Review.

19.

The enhanced oral response to the 5-HT2 agonist Ro 60-0175 in parkinsonian rats involves the entopeduncular nucleus: electrophysiological correlates.

Lagière M, Navailles S, Mignon L, Roumegous A, Chesselet MF, De Deurwaerdère P.

Exp Brain Res. 2013 Oct;230(4):513-24. doi: 10.1007/s00221-013-3478-4. Epub 2013 Mar 28.

PMID:
23535834
20.

PACAP deficiency sensitizes nigrostriatal dopaminergic neurons to paraquat-induced damage and modulates central and peripheral inflammatory activation in mice.

Watson MB, Nobuta H, Abad C, Lee SK, Bala N, Zhu C, Richter F, Chesselet MF, Waschek JA.

Neuroscience. 2013 Jun 14;240:277-86. doi: 10.1016/j.neuroscience.2013.03.002. Epub 2013 Mar 14.

21.

Mice overexpressing wild-type human alpha-synuclein display alterations in colonic myenteric ganglia and defecation.

Wang L, Magen I, Yuan PQ, Subramaniam SR, Richter F, Chesselet MF, Taché Y.

Neurogastroenterol Motil. 2012 Sep;24(9):e425-36. doi: 10.1111/j.1365-2982.2012.01974.x. Epub 2012 Jul 11.

22.

Regionally-specific microglial activation in young mice over-expressing human wildtype alpha-synuclein.

Watson MB, Richter F, Lee SK, Gabby L, Wu J, Masliah E, Effros RB, Chesselet MF.

Exp Neurol. 2012 Oct;237(2):318-34. doi: 10.1016/j.expneurol.2012.06.025. Epub 2012 Jun 27.

23.

Serotonin2C ligands exhibiting full negative and positive intrinsic activity elicit purposeless oral movements in rats: distinct effects of agonists and inverse agonists in a rat model of Parkinson's disease.

Navailles S, Lagière M, Roumegous A, Polito M, Boujema MB, Cador M, Dunlop J, Chesselet MF, Millan MJ, De Deurwaerdère P.

Int J Neuropsychopharmacol. 2013 Apr;16(3):593-606. doi: 10.1017/S1461145712000417. Epub 2012 May 3.

PMID:
22717119
24.

Improvement of neuropathology and transcriptional deficits in CAG 140 knock-in mice supports a beneficial effect of dietary curcumin in Huntington's disease.

Hickey MA, Zhu C, Medvedeva V, Lerner RP, Patassini S, Franich NR, Maiti P, Frautschy SA, Zeitlin S, Levine MS, Chesselet MF.

Mol Neurodegener. 2012 Apr 4;7:12. doi: 10.1186/1750-1326-7-12.

25.

Animal models of neurological disorders.

Chesselet MF, Carmichael ST.

Neurotherapeutics. 2012 Apr;9(2):241-4. doi: 10.1007/s13311-012-0118-9. No abstract available.

26.

Cognitive deficits in a mouse model of pre-manifest Parkinson's disease.

Magen I, Fleming SM, Zhu C, Garcia EC, Cardiff KM, Dinh D, De La Rosa K, Sanchez M, Torres ER, Masliah E, Jentsch JD, Chesselet MF.

Eur J Neurosci. 2012 Mar;35(6):870-82. doi: 10.1111/j.1460-9568.2012.08012.x. Epub 2012 Feb 22.

27.

A progressive mouse model of Parkinson's disease: the Thy1-aSyn ("Line 61") mice.

Chesselet MF, Richter F, Zhu C, Magen I, Watson MB, Subramaniam SR.

Neurotherapeutics. 2012 Apr;9(2):297-314. doi: 10.1007/s13311-012-0104-2. Review.

28.

Striatal atrophy and dendritic alterations in a knock-in mouse model of Huntington's disease.

Lerner RP, Trejo Martinez Ldel C, Zhu C, Chesselet MF, Hickey MA.

Brain Res Bull. 2012 Apr 10;87(6):571-8. doi: 10.1016/j.brainresbull.2012.01.012. Epub 2012 Feb 4.

29.

Animal models of the non-motor features of Parkinson's disease.

McDowell K, Chesselet MF.

Neurobiol Dis. 2012 Jun;46(3):597-606. doi: 10.1016/j.nbd.2011.12.040. Epub 2012 Jan 3. Review.

30.

Analysis of striatal transcriptome in mice overexpressing human wild-type alpha-synuclein supports synaptic dysfunction and suggests mechanisms of neuroprotection for striatal neurons.

Cabeza-Arvelaiz Y, Fleming SM, Richter F, Masliah E, Chesselet MF, Schiestl RH.

Mol Neurodegener. 2011 Dec 13;6:83. doi: 10.1186/1750-1326-6-83.

31.

Modelling of Parkinson's disease in mice.

Chesselet MF, Richter F.

Lancet Neurol. 2011 Dec;10(12):1108-18. doi: 10.1016/S1474-4422(11)70227-7. Review.

PMID:
22094131
32.

Evidence for behavioral benefits of early dietary supplementation with CoEnzymeQ10 in a slowly progressing mouse model of Huntington's disease.

Hickey MA, Zhu C, Medvedeva V, Franich NR, Levine MS, Chesselet MF.

Mol Cell Neurosci. 2012 Feb;49(2):149-57. doi: 10.1016/j.mcn.2011.10.007. Epub 2011 Oct 20.

33.

Traumatic brain injury in adult rats causes progressive nigrostriatal dopaminergic cell loss and enhanced vulnerability to the pesticide paraquat.

Hutson CB, Lazo CR, Mortazavi F, Giza CC, Hovda D, Chesselet MF.

J Neurotrauma. 2011 Sep;28(9):1783-801. doi: 10.1089/neu.2010.1723.

34.

Elevated tonic extracellular dopamine concentration and altered dopamine modulation of synaptic activity precede dopamine loss in the striatum of mice overexpressing human α-synuclein.

Lam HA, Wu N, Cely I, Kelly RL, Hean S, Richter F, Magen I, Cepeda C, Ackerson LC, Walwyn W, Masliah E, Chesselet MF, Levine MS, Maidment NT.

J Neurosci Res. 2011 Jul;89(7):1091-102. doi: 10.1002/jnr.22611. Epub 2011 Apr 12.

35.

A pilot trial of the microtubule-interacting peptide (NAP) in mice overexpressing alpha-synuclein shows improvement in motor function and reduction of alpha-synuclein inclusions.

Fleming SM, Mulligan CK, Richter F, Mortazavi F, Lemesre V, Frias C, Zhu C, Stewart A, Gozes I, Morimoto B, Chesselet MF.

Mol Cell Neurosci. 2011 Mar;46(3):597-606. doi: 10.1016/j.mcn.2010.12.011. Epub 2010 Dec 27.

36.

Mouse models of cognitive deficits due to alpha-synuclein pathology.

Magen I, Chesselet MF.

J Parkinsons Dis. 2011;1(3):217-27. doi: 10.3233/JPD-2011-11043. Review.

PMID:
23939303
37.

Genetic mouse models of Parkinson's disease The state of the art.

Magen I, Chesselet MF.

Prog Brain Res. 2010;184:53-87. doi: 10.1016/S0079-6123(10)84004-X. Review.

PMID:
20887870
38.

Selective blockade of serotonin 2C receptor enhances Fos expression specifically in the striatum and the subthalamic nucleus within the basal ganglia.

De Deurwaerdère P, Le Moine C, Chesselet MF.

Neurosci Lett. 2010 Jan 22;469(2):251-5. doi: 10.1016/j.neulet.2009.12.006. Epub 2009 Dec 11.

PMID:
20004702
39.

Context dependent neuroprotective properties of prion protein (PrP).

Steele AD, Zhou Z, Jackson WS, Zhu C, Auluck P, Moskowitz MA, Chesselet MF, Lindquist S.

Prion. 2009 Oct-Dec;3(4):240-9. Epub 2009 Oct 16.

40.

Neuronal NOS and cyclooxygenase-2 contribute to DNA damage in a mouse model of Parkinson disease.

Hoang T, Choi DK, Nagai M, Wu DC, Nagata T, Prou D, Wilson GL, Vila M, Jackson-Lewis V, Dawson VL, Dawson TM, Chesselet MF, Przedborski S.

Free Radic Biol Med. 2009 Oct 1;47(7):1049-56. doi: 10.1016/j.freeradbiomed.2009.07.013. Epub 2009 Jul 17.

41.

Neurons express hemoglobin alpha- and beta-chains in rat and human brains.

Richter F, Meurers BH, Zhu C, Medvedeva VP, Chesselet MF.

J Comp Neurol. 2009 Aug 10;515(5):538-47. doi: 10.1002/cne.22062.

42.

Bacterial artificial chromosome transgenic mice expressing a truncated mutant parkin exhibit age-dependent hypokinetic motor deficits, dopaminergic neuron degeneration, and accumulation of proteinase K-resistant alpha-synuclein.

Lu XH, Fleming SM, Meurers B, Ackerson LC, Mortazavi F, Lo V, Hernandez D, Sulzer D, Jackson GR, Maidment NT, Chesselet MF, Yang XW.

J Neurosci. 2009 Feb 18;29(7):1962-76. doi: 10.1523/JNEUROSCI.5351-08.2009.

43.

Adipose tissue dysfunction tracks disease progression in two Huntington's disease mouse models.

Phan J, Hickey MA, Zhang P, Chesselet MF, Reue K.

Hum Mol Genet. 2009 Mar 15;18(6):1006-16. doi: 10.1093/hmg/ddn428. Epub 2009 Jan 5.

44.

Low dose rotenone treatment causes selective transcriptional activation of cell death related pathways in dopaminergic neurons in vivo.

Meurers BH, Zhu C, Fernagut PO, Richter F, Hsia YC, Fleming SM, Oh M, Elashoff D, Dicarlo CD, Seaman RL, Chesselet MF.

Neurobiol Dis. 2009 Feb;33(2):182-92. doi: 10.1016/j.nbd.2008.10.001. Epub 2008 Oct 26.

45.

Ziram causes dopaminergic cell damage by inhibiting E1 ligase of the proteasome.

Chou AP, Maidment N, Klintenberg R, Casida JE, Li S, Fitzmaurice AG, Fernagut PO, Mortazavi F, Chesselet MF, Bronstein JM.

J Biol Chem. 2008 Dec 12;283(50):34696-703. doi: 10.1074/jbc.M802210200. Epub 2008 Sep 25.

46.

Extensive early motor and non-motor behavioral deficits are followed by striatal neuronal loss in knock-in Huntington's disease mice.

Hickey MA, Kosmalska A, Enayati J, Cohen R, Zeitlin S, Levine MS, Chesselet MF.

Neuroscience. 2008 Nov 11;157(1):280-95. doi: 10.1016/j.neuroscience.2008.08.041. Epub 2008 Aug 27.

47.

Olfactory deficits in mice overexpressing human wildtype alpha-synuclein.

Fleming SM, Tetreault NA, Mulligan CK, Hutson CB, Masliah E, Chesselet MF.

Eur J Neurosci. 2008 Jul;28(2):247-56. doi: 10.1111/j.1460-9568.2008.06346.x.

48.

Strengths and limitations of genetic mouse models of Parkinson's disease.

Chesselet MF, Fleming S, Mortazavi F, Meurers B.

Parkinsonism Relat Disord. 2008;14 Suppl 2:S84-7. doi: 10.1016/j.parkreldis.2008.04.004. Epub 2008 Jun 27. Review.

49.

Abnormal colonic motility in mice overexpressing human wild-type alpha-synuclein.

Wang L, Fleming SM, Chesselet MF, Taché Y.

Neuroreport. 2008 May 28;19(8):873-6. doi: 10.1097/WNR.0b013e3282ffda5e.

50.

Detection of DNA damage in tissue sections by in situ nick translation.

Chesselet MF, MacKenzie L, Hoang T.

Curr Protoc Neurosci. 2001 Nov;Chapter 1:Unit 1.9. doi: 10.1002/0471142301.ns0109s16.

PMID:
18428455

Supplemental Content

Loading ...
Support Center